JP2011513484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513484A5 JP2011513484A5 JP2010550687A JP2010550687A JP2011513484A5 JP 2011513484 A5 JP2011513484 A5 JP 2011513484A5 JP 2010550687 A JP2010550687 A JP 2010550687A JP 2010550687 A JP2010550687 A JP 2010550687A JP 2011513484 A5 JP2011513484 A5 JP 2011513484A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- receptor
- channel
- voltage
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 49
- 102000005962 receptors Human genes 0.000 claims 27
- 108020003175 receptors Proteins 0.000 claims 27
- 238000000034 method Methods 0.000 claims 26
- 108091006146 Channels Proteins 0.000 claims 18
- -1 AM404 Chemical compound 0.000 claims 16
- 108090000862 Ion Channels Proteins 0.000 claims 15
- 102000004310 Ion Channels Human genes 0.000 claims 15
- 239000012190 activator Substances 0.000 claims 10
- 208000002193 Pain Diseases 0.000 claims 9
- 210000000929 nociceptor Anatomy 0.000 claims 9
- 108091008700 nociceptors Proteins 0.000 claims 9
- BLZVCIGGICSWIG-UHFFFAOYSA-N 2-aminoethoxydiphenylborane Chemical compound C=1C=CC=CC=1B(OCCN)C1=CC=CC=C1 BLZVCIGGICSWIG-UHFFFAOYSA-N 0.000 claims 8
- 208000003251 Pruritus Diseases 0.000 claims 8
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 7
- 102000003610 TRPM8 Human genes 0.000 claims 7
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 7
- 101150111302 Trpm8 gene Proteins 0.000 claims 7
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 6
- VQEONGKQWIFHMN-UHFFFAOYSA-N Nordihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCC(C)C)=CC=C1O VQEONGKQWIFHMN-UHFFFAOYSA-N 0.000 claims 6
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 6
- 229960004919 procaine Drugs 0.000 claims 6
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims 5
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 5
- 102000003566 TRPV1 Human genes 0.000 claims 5
- 101150016206 Trpv1 gene Proteins 0.000 claims 5
- 229960003831 articaine Drugs 0.000 claims 5
- 229960003150 bupivacaine Drugs 0.000 claims 5
- 229960004194 lidocaine Drugs 0.000 claims 5
- 210000004379 membrane Anatomy 0.000 claims 5
- 239000012528 membrane Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 5
- IITCVPTZKLXSKQ-ZSVIJTOTSA-N 6'-iodoresiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(OC(O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1I IITCVPTZKLXSKQ-ZSVIJTOTSA-N 0.000 claims 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims 4
- 229920001144 Hydroxy alpha sanshool Polymers 0.000 claims 4
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 claims 4
- OPZKBPQVWDSATI-KHPPLWFESA-N N-Vanillyloleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-KHPPLWFESA-N 0.000 claims 4
- QQBPLXNESPTPNU-KTKRTIGZSA-N N-oleoyldopamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCC1=CC=C(O)C(O)=C1 QQBPLXNESPTPNU-KTKRTIGZSA-N 0.000 claims 4
- ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 claims 4
- FADFGCOCHHNRHF-VAWYXSNFSA-N [10]-Shogaol Chemical compound CCCCCCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 FADFGCOCHHNRHF-VAWYXSNFSA-N 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- PFRGXCVKLLPLIP-UHFFFAOYSA-N diallyl disulfide Chemical compound C=CCSSCC=C PFRGXCVKLLPLIP-UHFFFAOYSA-N 0.000 claims 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims 4
- LHFKHAVGGJJQFF-UHFFFAOYSA-N hydroxyl-alpha-sanshool Natural products CC=CC=CC=CCCC=CC(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UHFFFAOYSA-N 0.000 claims 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims 4
- OGRGWTXWAZBJKF-JXWJAAHMSA-N phorbol 12-phenylacetate 13-acetate 20-homovanillate Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]3(O)[C@H](C)[C@@H](OC(=O)CC=4C=CC=CC=4)[C@@]4(OC(C)=O)C(C)(C)[C@H]4[C@@H]3C=2)=C1 OGRGWTXWAZBJKF-JXWJAAHMSA-N 0.000 claims 4
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims 4
- 229960001807 prilocaine Drugs 0.000 claims 4
- 230000001823 pruritic effect Effects 0.000 claims 4
- 229960002372 tetracaine Drugs 0.000 claims 4
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims 4
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 claims 3
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims 3
- 241000723346 Cinnamomum camphora Species 0.000 claims 3
- KEECCEWTUVWFCV-UHFFFAOYSA-N N-acetylprocainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1 KEECCEWTUVWFCV-UHFFFAOYSA-N 0.000 claims 3
- FTLDJPRFCGDUFH-UHFFFAOYSA-N Oxethazaine Chemical compound C=1C=CC=CC=1CC(C)(C)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1 FTLDJPRFCGDUFH-UHFFFAOYSA-N 0.000 claims 3
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims 3
- 108010025083 TRPV1 receptor Proteins 0.000 claims 3
- NZLBHDRPUJLHCE-UHFFFAOYSA-N aprindine Chemical compound C1C2=CC=CC=C2CC1N(CCCN(CC)CC)C1=CC=CC=C1 NZLBHDRPUJLHCE-UHFFFAOYSA-N 0.000 claims 3
- 229960004957 aprindine Drugs 0.000 claims 3
- 229960005274 benzocaine Drugs 0.000 claims 3
- 229960000846 camphor Drugs 0.000 claims 3
- 229930008380 camphor Natural products 0.000 claims 3
- 229960002504 capsaicin Drugs 0.000 claims 3
- 235000017663 capsaicin Nutrition 0.000 claims 3
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 claims 3
- 229960001747 cinchocaine Drugs 0.000 claims 3
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims 3
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 3
- 229960004022 clotrimazole Drugs 0.000 claims 3
- 229960003920 cocaine Drugs 0.000 claims 3
- XJQPQKLURWNAAH-UHFFFAOYSA-N dihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCC(C)C)=CC=C1O XJQPQKLURWNAAH-UHFFFAOYSA-N 0.000 claims 3
- RBCYRZPENADQGZ-UHFFFAOYSA-N dihydrocapsaicin Natural products COC1=CC(COC(=O)CCCCCCC(C)C)=CC=C1O RBCYRZPENADQGZ-UHFFFAOYSA-N 0.000 claims 3
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 claims 3
- 229950010160 dimethocaine Drugs 0.000 claims 3
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 claims 3
- 229960001142 encainide Drugs 0.000 claims 3
- 229960003404 mexiletine Drugs 0.000 claims 3
- 229960000986 oxetacaine Drugs 0.000 claims 3
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 claims 3
- 229960000244 procainamide Drugs 0.000 claims 3
- 229960003981 proparacaine Drugs 0.000 claims 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims 2
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 2
- AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 claims 2
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 claims 2
- 102100027782 ATP synthase-coupling factor 6, mitochondrial Human genes 0.000 claims 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims 2
- 239000005770 Eugenol Substances 0.000 claims 2
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 claims 2
- 239000005792 Geraniol Substances 0.000 claims 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims 2
- 101000936965 Homo sapiens ATP synthase-coupling factor 6, mitochondrial Proteins 0.000 claims 2
- 102000003820 Lipoxygenases Human genes 0.000 claims 2
- 108090000128 Lipoxygenases Proteins 0.000 claims 2
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 claims 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims 2
- 102000002294 Purinergic P2X Receptors Human genes 0.000 claims 2
- 108010000836 Purinergic P2X Receptors Proteins 0.000 claims 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 2
- WSINRQSTSKCAEN-UGTJMOTHSA-N [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-[[hydroxy-[hydroxy(phosphonooxy)phosphoryl]oxyphosphoryl]oxymethyl]oxolan-3-yl] 4-benzoylbenzoate Chemical compound O([C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 WSINRQSTSKCAEN-UGTJMOTHSA-N 0.000 claims 2
- KDYVIORLSJSMTG-UHFFFAOYSA-N [2-[(3,4-dimethylphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methylcarbamothioylamino]propyl] 2,2-dimethylpropanoate Chemical compound C1=C(O)C(OC)=CC(CNC(=S)NCC(COC(=O)C(C)(C)C)CC=2C=C(C)C(C)=CC=2)=C1 KDYVIORLSJSMTG-UHFFFAOYSA-N 0.000 claims 2
- XNOBOKJVOTYSJV-KQYNXXCUSA-N [[(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XNOBOKJVOTYSJV-KQYNXXCUSA-N 0.000 claims 2
- AYJBWCXXFCSXNE-UHFFFAOYSA-N [hydroxy(phosphonooxy)phosphinothioyl] dihydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=S)OP(O)(O)=O AYJBWCXXFCSXNE-UHFFFAOYSA-N 0.000 claims 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 claims 2
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 claims 2
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 claims 2
- 229960003369 butacaine Drugs 0.000 claims 2
- 229960002023 chloroprocaine Drugs 0.000 claims 2
- 229960005233 cineole Drugs 0.000 claims 2
- 229940117916 cinnamic aldehyde Drugs 0.000 claims 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims 2
- 239000010630 cinnamon oil Substances 0.000 claims 2
- 239000010634 clove oil Substances 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 229960003976 etidocaine Drugs 0.000 claims 2
- 229960002217 eugenol Drugs 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 229940113087 geraniol Drugs 0.000 claims 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims 2
- 235000002780 gingerol Nutrition 0.000 claims 2
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 229960004288 levobupivacaine Drugs 0.000 claims 2
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims 2
- 229930007744 linalool Natural products 0.000 claims 2
- 229940041616 menthol Drugs 0.000 claims 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- 239000008164 mustard oil Substances 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- OPZKBPQVWDSATI-UHFFFAOYSA-N oleoyl vanillylamide Natural products CCCCCCCCC=CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 OPZKBPQVWDSATI-UHFFFAOYSA-N 0.000 claims 2
- 229950010717 olvanil Drugs 0.000 claims 2
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 2
- 229940075559 piperine Drugs 0.000 claims 2
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 2
- 235000019100 piperine Nutrition 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229950003255 propoxycaine Drugs 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 2
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 claims 2
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 claims 2
- 229940073454 resiniferatoxin Drugs 0.000 claims 2
- 229960001549 ropivacaine Drugs 0.000 claims 2
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- OAHWPNUPCSDOGU-UHFFFAOYSA-N trans-10-shogaol Natural products CCCCCCCCCC=CC(=O)CCc1ccc(O)c(CO)c1 OAHWPNUPCSDOGU-UHFFFAOYSA-N 0.000 claims 2
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 claims 2
- 229950002569 trimecaine Drugs 0.000 claims 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 2
- 239000009637 wintergreen oil Substances 0.000 claims 2
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 claims 1
- MRDJEHJOSCNEAJ-UHFFFAOYSA-N 1-[(4-tert-butylphenyl)methyl]-3-[(4-hydroxy-3-methoxyphenyl)methyl]thiourea Chemical compound C1=C(O)C(OC)=CC(CNC(=S)NCC=2C=CC(=CC=2)C(C)(C)C)=C1 MRDJEHJOSCNEAJ-UHFFFAOYSA-N 0.000 claims 1
- ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 12(S)-HPETE Chemical compound CCCCC\C=C/C[C@H](OO)\C=C\C=C/C\C=C/CCCC(O)=O ZIOZYRSDNLNNNJ-LQWMCKPYSA-N 0.000 claims 1
- DCZJQMPBINFCEC-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-amino-2-butoxybenzoate;hydrochloride Chemical compound [Cl-].CCCCOC1=CC(N)=CC=C1C(=O)OCC[NH+](CC)CC DCZJQMPBINFCEC-UHFFFAOYSA-N 0.000 claims 1
- STRVVRPNBAHXRJ-UHFFFAOYSA-N 2-hydroxynon-2-enal Chemical compound CCCCCCC=C(O)C=O STRVVRPNBAHXRJ-UHFFFAOYSA-N 0.000 claims 1
- XPYXSZDENRDLKD-UHFFFAOYSA-N 2-octylguanidine Chemical compound CCCCCCCCN=C(N)N XPYXSZDENRDLKD-UHFFFAOYSA-N 0.000 claims 1
- 125000006185 3,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 claims 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical group C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- QYUXPWDVDMSTKR-UHFFFAOYSA-O [2-(2,6-dimethylanilino)-2-oxoethyl]-trimethylammonium Chemical compound CC1=CC=CC(C)=C1NC(=O)C[N+](C)(C)C QYUXPWDVDMSTKR-UHFFFAOYSA-O 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229960001441 aminoacridine Drugs 0.000 claims 1
- FYJJXENSONZJRG-UHFFFAOYSA-N bencyclane Chemical compound C=1C=CC=CC=1CC1(OCCCN(C)C)CCCCCC1 FYJJXENSONZJRG-UHFFFAOYSA-N 0.000 claims 1
- 229960000945 bencyclane Drugs 0.000 claims 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical group C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 claims 1
- 229960003665 bepridil Drugs 0.000 claims 1
- AAQOQKQBGPPFNS-UHFFFAOYSA-N bretylium Chemical compound CC[N+](C)(C)CC1=CC=CC=C1Br AAQOQKQBGPPFNS-UHFFFAOYSA-N 0.000 claims 1
- 229960002624 bretylium tosilate Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 229960004741 cyclomethycaine Drugs 0.000 claims 1
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 229960000385 dyclonine Drugs 0.000 claims 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims 1
- 229960000326 flunarizine Drugs 0.000 claims 1
- 229960000457 gallopamil Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- SNDDYCQJMICBCK-UHFFFAOYSA-M n-benzyl-n-[3-(2-methylpropoxy)-2-(1-methylpyrrolidin-1-ium-1-yl)propyl]aniline;bromide Chemical compound [Br-].C1CCC[N+]1(C)C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 SNDDYCQJMICBCK-UHFFFAOYSA-M 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 229940118177 nesacaine Drugs 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 claims 1
- 229960005457 pancuronium Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 229960001404 quinidine Drugs 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960002872 tocainide Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6901808P | 2008-03-11 | 2008-03-11 | |
| PCT/US2009/001541 WO2009114139A2 (en) | 2008-03-11 | 2009-03-11 | Methods, compositions, and kits for treating pain and pruritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011513484A JP2011513484A (ja) | 2011-04-28 |
| JP2011513484A5 true JP2011513484A5 (enExample) | 2012-04-26 |
Family
ID=41065720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010550687A Pending JP2011513484A (ja) | 2008-03-11 | 2009-03-11 | 疼痛および掻痒症を治療するための方法、組成物、およびキット |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110086818A1 (enExample) |
| EP (1) | EP2271329A4 (enExample) |
| JP (1) | JP2011513484A (enExample) |
| KR (1) | KR20110044166A (enExample) |
| CN (1) | CN102112121A (enExample) |
| AU (1) | AU2009223739A1 (enExample) |
| BR (1) | BRPI0909627A2 (enExample) |
| CA (1) | CA2717042A1 (enExample) |
| IL (1) | IL208027A0 (enExample) |
| MX (1) | MX2010009951A (enExample) |
| WO (1) | WO2009114139A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2101819B1 (en) | 2006-11-20 | 2013-01-09 | President and Fellows of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
| WO2010085589A2 (en) | 2009-01-22 | 2010-07-29 | G&H Brands Llc | Desensitizing drug product |
| EP2995303A1 (en) | 2009-07-10 | 2016-03-16 | President and Fellows of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| JP5832856B2 (ja) * | 2010-12-15 | 2015-12-16 | 久光製薬株式会社 | 局所鎮痛作用増強剤及び局所鎮痛キット |
| CN103547566B (zh) | 2011-02-18 | 2017-05-31 | 阿萨纳生物科技有限责任公司 | 氨基茚满化合物及其治疗疼痛的用途 |
| ES2596215T3 (es) | 2011-10-24 | 2017-01-05 | Asana Biosciences, Llc | Ciclohexilaminas |
| US8779003B2 (en) | 2011-12-29 | 2014-07-15 | Mackay Memorial Hospital | Method and composition for prolonging analgesic effect of local anesthetic |
| TWI603957B (zh) | 2012-08-15 | 2017-11-01 | 阿沙納生物科學有限責任公司 | 胺基氫茚化合物用於治療膀胱過動症及間質性膀胱炎之用途 |
| ES2675215T3 (es) | 2013-02-08 | 2018-07-09 | General Mills, Inc. | Productos alimentarios reducidos en sodio |
| AU2015247815A1 (en) * | 2014-04-14 | 2016-11-03 | Flex Pharma, Inc. | Ion channel activators and methods of use |
| WO2017024037A1 (en) * | 2015-08-03 | 2017-02-09 | President And Fellows Of Harvard College | Charged ion channel blockers and methods for use |
| CN106214678B (zh) * | 2016-07-26 | 2020-12-29 | 上海璃道医药科技有限公司 | 苯酮类药物的用途 |
| US11253493B2 (en) | 2017-01-23 | 2022-02-22 | Cliff-Cartwright Corporation | Compositions and methods affecting exercise performance |
| KR101877002B1 (ko) * | 2017-03-06 | 2018-07-12 | 서울대학교 산학협력단 | 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법 |
| KR101867779B1 (ko) * | 2017-12-08 | 2018-06-19 | 서울대학교산학협력단 | 피라졸 유도체를 유효성분으로 함유하는 소양증의 예방 또는 치료용 약학적 조성물 및 이를 검출하기 위한 스크리닝 방법 |
| WO2019144139A1 (en) * | 2018-01-22 | 2019-07-25 | Oregon State University | Immunogenic compositions comprising mycobacterium bovis surface proteins and uses thereof |
| US12023332B2 (en) | 2018-03-05 | 2024-07-02 | Wylder Nation Foundation | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin |
| KR102954667B1 (ko) * | 2018-08-15 | 2026-04-17 | 파마실 아베 | 치환된 벤즈아미드 및 치료법에서 이의 용도 |
| CN109498604A (zh) * | 2018-12-24 | 2019-03-22 | 复旦大学 | 香叶醇新用途，预防和治疗非疾病引起的瘙痒症的配制品及方法 |
| BR112021017809A2 (pt) | 2019-03-11 | 2021-11-23 | Nocion Therapeutics Inc | Bloqueadores de canais iônicos substituídos por éster e métodos para uso |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| MA55307A (fr) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueurs de canaux ioniques chargés et procédés d'utilisation |
| EP3937945A4 (en) * | 2019-03-11 | 2023-01-04 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| WO2021091585A1 (en) | 2019-11-06 | 2021-05-14 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US20230165812A1 (en) * | 2020-02-27 | 2023-06-01 | President And Fellows Of Harvard College | Nociceptor neurons control cancer immunosurveillance |
| JP2023515874A (ja) * | 2020-03-04 | 2023-04-14 | ノイキュアズ，インコーポレーテッド | Ｔｒｐｖ１調節物質の投与に関連する交感神経興奮を防止するためのｑｘ３１４の使用 |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| JP7708777B2 (ja) | 2020-03-11 | 2025-07-15 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| CN113509457B (zh) * | 2020-09-07 | 2023-03-21 | 四川昇嘉科技有限公司 | 山椒素在制备治疗湿疹的药物中的用途 |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413961B1 (en) * | 1995-12-12 | 2002-07-02 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain and inflammation |
| MXPA02006051A (es) * | 1999-12-15 | 2004-08-23 | Ucb Farchim Sa | Compuestos de amonio cuaternario ciclico. |
| WO2002089849A1 (en) * | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| EP1610742B1 (en) * | 2003-04-10 | 2015-01-21 | Neurogesx, Inc. | Uses and compositions for administration of capsaicin |
| ES2223277B1 (es) * | 2003-06-19 | 2006-03-01 | Fernando Bouffard Fita | Composicion anestesica para administracion topica. |
| EP1713450B1 (en) * | 2004-01-30 | 2021-10-06 | Corium, Inc. | Rapidly dissolving film for delivery of an active agent |
| JP5148271B2 (ja) * | 2004-06-02 | 2013-02-20 | ニューロジズエックス，インコーポレーテッド | 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物 |
| EP2101819B1 (en) * | 2006-11-20 | 2013-01-09 | President and Fellows of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
-
2009
- 2009-03-11 MX MX2010009951A patent/MX2010009951A/es not_active Application Discontinuation
- 2009-03-11 CA CA2717042A patent/CA2717042A1/en not_active Abandoned
- 2009-03-11 BR BRPI0909627A patent/BRPI0909627A2/pt not_active IP Right Cessation
- 2009-03-11 CN CN200980117485XA patent/CN102112121A/zh active Pending
- 2009-03-11 WO PCT/US2009/001541 patent/WO2009114139A2/en not_active Ceased
- 2009-03-11 JP JP2010550687A patent/JP2011513484A/ja active Pending
- 2009-03-11 US US12/922,038 patent/US20110086818A1/en not_active Abandoned
- 2009-03-11 EP EP09718704A patent/EP2271329A4/en not_active Withdrawn
- 2009-03-11 KR KR1020107022652A patent/KR20110044166A/ko not_active Withdrawn
- 2009-03-11 AU AU2009223739A patent/AU2009223739A1/en not_active Abandoned
-
2010
- 2010-09-07 IL IL208027A patent/IL208027A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532887A5 (enExample) | ||
| AU2010271269B2 (en) | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | |
| Walpole et al. | Analogs of capsaicin with agonist activity as novel analgesic agents; structure-activity studies. 2. The amide bond" B-region" | |
| Trivedi et al. | Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects | |
| US9265734B2 (en) | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors | |
| JP7571947B2 (ja) | ヒストンアセチルトランスフェラーゼ活性化剤及び組成物並びにそれらの使用 | |
| NZ596863A (en) | Alkanoylamino benzamide aniline hdac inhibitor compounds | |
| US10925865B2 (en) | Charged ion channel blockers and methods for use | |
| EP3859841A4 (en) | ACTIVE MATERIAL, POSITIVE ELECTRODE MIXTURE AND SOLID STATE BATTERY WITH THIS ACTIVE MATERIAL | |
| HRP20171517T1 (hr) | 1-hidroksibenzooksaboroli kao antiparazitska sredstva | |
| JP2010530847A5 (enExample) | ||
| AU2020237474C1 (en) | Charged ion channel blockers and methods for use | |
| AU2020235888A1 (en) | Charged ION channel blockers and methods for use | |
| RU2016151688A (ru) | Аминоиндановые соединения и их применение при лечении боли | |
| EA200900605A1 (ru) | Новые производные фенилсульфамоил бензамидов в качестве антагонистов брадикининовых рецепторов | |
| US11332446B2 (en) | Charged ion channel blockers and methods for use | |
| WO2021092148A1 (en) | Phosphonium ion channel blockers and methods for use | |
| EA200900604A1 (ru) | Производные бензамидов в качестве антагонистов брадикининовых рецепторов | |
| AU2020239060A1 (en) | Ester substituted ion channel blockers and methods for use | |
| RU2008144952A (ru) | Производные аминометилпиридина, их получение и их применение в терапии | |
| CN111615383A (zh) | 药物组合物、贴剂及其制备方法、镇痛方法、应用 | |
| EA202190077A1 (ru) | Ингибиторы гистондеацетилазы | |
| Yan et al. | Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1 | |
| WO2008089436A3 (en) | Crystalline forms of histone deacetylase inhibitors | |
| RU2013105317A (ru) | Производное n-гидроксиформамида и содержащее его лекарственное средство |